GLPwatch
Papers (10409)
Page 111 of 174, ranked by citation count.
- Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- GLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.
- Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.
- Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction.
- Prehospital exenatide in hyperglycemic stroke-A randomized trial.
- The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
- Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
- Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.
- Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.
- Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.
- Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission.
- Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and <i>β</i>-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.
- Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.
- Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.
- Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).
- Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.
- Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells.
- Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue.
- Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
- Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
- Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study.
- GLP-1 receptor agonists for the treatment of alcohol use disorder.
- Exenatide extended-release; clinical trials, patient preference, and economic considerations.
- Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
- Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
- Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.
- Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.
- Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
- Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
- Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
- Tirzepatide (Zepbound) for chronic weight management.
- Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.
- Lack of Benefit for Liraglutide in Heart Failure.
- Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with <sup>111</sup>In-labeled exendin-4.
- Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.
- Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery.
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
- Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
- Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.
- NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
- Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
- Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
- The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.
- Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide "For Research Purposes".
- Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?
- Tirzepatide for type 2 diabetes.
- The estrogenic reduction in water intake stimulated by dehydration involves estrogen receptor alpha and a potential role for GLP-1.
- Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
- Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine.
- Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
- Electrochemical Sensing of the Peptide Drug Exendin-4 Using a Versatile Nucleic Acid Nanostructure.
- HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
- The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.
- Novel oral agents in anti-obesity pharmacotherapy: A narrative review.
- Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).